Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

2,736 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.
Hill G, Cihlar T, Oo C, Ho ES, Prior K, Wiltshire H, Barrett J, Liu B, Ward P. Hill G, et al. Drug Metab Dispos. 2002 Jan;30(1):13-9. doi: 10.1124/dmd.30.1.13. Drug Metab Dispos. 2002. PMID: 11744606 Clinical Trial.
Ro 64-0802 was found to be a low-efficiency substrate for hOAT1 and a very weak inhibitor of hOAT1-mediated transport of p-aminohippuric acid (PAH). ...
Ro 64-0802 was found to be a low-efficiency substrate for hOAT1 and a very weak inhibitor of hOAT1-mediated transport of p-aminohippu …
Safety and pharmacology of oseltamivir in clinical use.
Dutkowski R, Thakrar B, Froehlich E, Suter P, Oo C, Ward P. Dutkowski R, et al. Drug Saf. 2003;26(11):787-801. doi: 10.2165/00002018-200326110-00004. Drug Saf. 2003. PMID: 12908848 Review.
Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.
Ward P, Small I, Smith J, Suter P, Dutkowski R. Ward P, et al. J Antimicrob Chemother. 2005 Feb;55 Suppl 1:i5-i21. doi: 10.1093/jac/dki018. J Antimicrob Chemother. 2005. PMID: 15709056 Review.
Lack of pharmacokinetic interaction between the oral anti-influenza prodrug oseltamivir and aspirin.
Oo C, Barrett J, Dorr A, Liu B, Ward P. Oo C, et al. Antimicrob Agents Chemother. 2002 Jun;46(6):1993-5. doi: 10.1128/aac.46.6.1993-1995.2002. Antimicrob Agents Chemother. 2002. PMID: 12019123 Free PMC article. Clinical Trial.
Role of picornaviruses in flu-like illnesses of adults enrolled in an oseltamivir treatment study who had no evidence of influenza virus infection.
Boivin G, Osterhaus AD, Gaudreau A, Jackson HC, Groen J, Ward P. Boivin G, et al. J Clin Microbiol. 2002 Feb;40(2):330-4. doi: 10.1128/jcm.40.2.330-334.2002. J Clin Microbiol. 2002. PMID: 11825938 Free PMC article. Clinical Trial.
The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis.
Robson R, Buttimore A, Lynn K, Brewster M, Ward P. Robson R, et al. Nephrol Dial Transplant. 2006 Sep;21(9):2556-62. doi: 10.1093/ndt/gfl267. Epub 2006 Jun 24. Nephrol Dial Transplant. 2006. PMID: 16799169 Clinical Trial.
Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.
Oo C, Hill G, Dorr A, Liu B, Boellner S, Ward P. Oo C, et al. Eur J Clin Pharmacol. 2003 Sep;59(5-6):411-5. doi: 10.1007/s00228-003-0639-6. Epub 2003 Aug 9. Eur J Clin Pharmacol. 2003. PMID: 12910331 Clinical Trial.
Effect of age and gender on tirilazad pharmacokinetics in humans.
Hulst LK, Fleishaker JC, Peters GR, Harry JD, Wright DM, Ward P. Hulst LK, et al. Clin Pharmacol Ther. 1994 Apr;55(4):378-84. doi: 10.1038/clpt.1994.45. Clin Pharmacol Ther. 1994. PMID: 8162663
Early administration of oral oseltamivir increases the benefits of influenza treatment.
Aoki FY, Macleod MD, Paggiaro P, Carewicz O, El Sawy A, Wat C, Griffiths M, Waalberg E, Ward P; IMPACT Study Group. Aoki FY, et al. J Antimicrob Chemother. 2003 Jan;51(1):123-9. doi: 10.1093/jac/dkg007. J Antimicrob Chemother. 2003. PMID: 12493796 Clinical Trial.
Earlier intervention was associated with shorter illness duration (P < 0.0001). Initiation of therapy within the first 12 h after fever onset reduced the total median illness duration by 74.6 h (3.1 days; 41%) more than intervention at 48 h. ...

Earlier intervention was associated with shorter illness duration (P < 0.0001). Initiation of therapy within the first 12 h after

2,736 results
Jump to page
Feedback